Residency · Residency · Otolaryngology

Laryngeal Cancer: Organ Preservation and Surgical Options

Overview

Laryngeal cancer is predominantly squamous cell carcinoma, arising most commonly in the glottis. Treatment strategies balance oncologic outcomes with organ preservation, voice quality, and swallowing function. The landmark VA Laryngeal Cancer Study and RTOG 91-11 established chemoradiation as a viable organ preservation strategy. However, the role of surgery, including total laryngectomy, remains critical for advanced and recurrent disease.

Anatomy

Supraglottis: epiglottis (suprahyoid and infrahyoid), aryepiglottic folds, arytenoids, false vocal folds, ventricle. Glottis: true vocal folds, anterior commissure, posterior commissure (interarytenoid area); extends 1 cm below the free edge of the vocal fold. Subglottis: from 1 cm below the vocal fold free edge to the inferior border of the cricoid cartilage.

Lymphatic Drainage

Glottis: minimal lymphatic drainage; nodal metastasis rare for T1-T2 (1-5%). Supraglottis: rich lymphatic network; bilateral drainage; nodal metastasis in 25-50% even at early stages. Subglottis: drains to paratracheal (level VI) and lower jugular nodes; relatively rare primary site.

Clinical Presentation

Glottic: hoarseness (early symptom); dysphagia and airway compromise in advanced disease. Supraglottic: sore throat, dysphagia, referred otalgia (via CN X/Arnold nerve); voice change is late; neck mass from nodal metastasis may be the presenting complaint. Subglottic: stridor, dyspnea; rare as a primary site.

Staging (AJCC 8th Edition)

Glottic Carcinoma

T1a: limited to one vocal fold, normal mobility. T1b: both vocal folds involved, normal mobility. T2: extends to supraglottis or subglottis, OR impaired vocal fold mobility. T3: vocal fold fixation, OR invasion of paraglottic space, OR minor thyroid cartilage erosion (inner cortex). T4a: invasion through thyroid cartilage, or extension beyond the larynx (trachea, deep tongue muscles, thyroid, esophagus, strap muscles). T4b: prevertebral space invasion, encasement of carotid artery, mediastinal invasion.

Supraglottic Carcinoma

T1: limited to one subsite, normal vocal fold mobility. T2: invades more than one subsite or extends beyond supraglottis, no vocal fold fixation. T3: vocal fold fixation, OR invasion of postcricoid area, pre-epiglottic space, or paraglottic space, OR minor thyroid cartilage erosion. T4a/T4b: similar to glottic staging.

Treatment of Early Glottic Carcinoma (T1-T2)

Radiation Therapy

T1 glottic: single modality radiation (66-70 Gy); local control 85-95%. T2 glottic: radiation alone; local control 70-80%. Voice outcomes generally excellent. Advantages: no surgery, preserved laryngeal framework, good voice. Disadvantages: daily treatment for 6-7 weeks, potential long-term effects (edema, chondronecrosis).

Endoscopic Laser Surgery (TLM)

CO2 laser excision via direct laryngoscopy. Suitable for T1-T2 lesions with adequate transoral exposure. Single-stage, outpatient procedure, Voice outcomes comparable to radiation in most studies. Advantage: preserves radiation as a future treatment option (salvage). Allows pathologic margin assessment.

Open Partial Laryngectomy

Rarely performed for early disease due to endoscopic and radiation options. Vertical partial laryngectomy (hemilaryngectomy): for T1-T2 glottic tumors limited to one fold.

Treatment of Advanced Laryngeal Carcinoma (T3-T4)

Organ Preservation: Chemoradiation [CONTROVERSY]

VA Laryngeal Cancer Study (1991)

Randomized trial: induction chemotherapy (cisplatin/5-FU) followed by radiation vs. total laryngectomy + adjuvant radiation. No survival difference, 64% laryngeal preservation rate in the chemotherapy arm, Established organ preservation as a viable paradigm.

RTOG 91-11 (2003, updated 2013)

Three arms: induction cisplatin/5-FU then radiation vs. concurrent cisplatin + radiation vs. radiation alone. Concurrent chemoradiation showed highest larynx preservation rate (84% at 2 years). No overall survival difference among groups (long-term follow-up showed a concerning trend of more non-cancer deaths in the concurrent chemoradiation arm). Concurrent cisplatin + radiation is the standard organ preservation protocol.

Patient Selection for Organ Preservation

T3 laryngeal SCC with functional larynx: standard indication. T4a: more controversial; high-volume T4a with cartilage destruction may benefit from primary surgery. Contraindications to organ preservation: Non-functional larynx (aspiration, fixed bilateral folds). Cartilage destruction through thyroid cartilage (relative). Severe medical comorbidity precluding chemotherapy. Patient preference for surgery.

Total Laryngectomy

Remains the definitive surgical treatment for advanced laryngeal cancer. Indications: T4a with cartilage destruction, failed organ preservation (salvage), non-functional larynx, recurrent disease after radiation. Results in permanent tracheostoma and loss of normal voice, Very high local control rate (>90%). Overall survival for advanced laryngeal cancer has declined since widespread adoption of organ preservation -- a subject of ongoing concern.

Voice Restoration After Total Laryngectomy

Tracheoesophageal puncture (TEP): primary (at time of laryngectomy) or secondary procedure; one-way valve (Blom-Singer or Provox) allows pulmonary air to vibrate the pharyngoesophageal (PE) segment for alaryngeal speech. Most reliable method; ~80-90% functional speech. Esophageal speech: swallowed air used to vibrate the PE segment; requires training; successful in ~30%. Electrolarynx: handheld device producing vibrations transmitted through neck tissue; immediately available; robotic voice quality.

Partial Laryngectomy (Open)

Supraglottic laryngectomy: for T1-T2 (select T3) supraglottic tumors; preserves vocal folds; requires adequate pulmonary function (aspiration risk during recovery). Supracricoid partial laryngectomy (SCPL): removes thyroid cartilage, true and false folds, +/- epiglottis; preserves at least one arytenoid; reconstructed with cricohyoidopexy (CHP) or cricohyoidoepiglottopexy (CHEP). Applicable for select T2-T3 glottic and transglottic tumors. Preserves voice and swallowing without tracheostomy (decannulated in most patients). Requires at least one functional arytenoid and intact cricoid.

Neck Management

Glottic T1-T2: elective neck treatment generally not required (low nodal rate). Glottic T3-T4: bilateral neck treatment (dissection or radiation). Supraglottic (all stages): bilateral neck treatment (high nodal rate); selective neck dissection levels II-IV.

Salvage Laryngectomy

For recurrence after radiation or chemoradiation. Higher complication rate than primary laryngectomy (30-60% wound complications). Pharyngocutaneous fistula: most common major complication (15-30%); increased risk after chemoradiation. Vascularized tissue interposition (pectoralis major flap) at the time of salvage may reduce fistula rates.

<image>Coronal diagram of the larynx showing the three subsites (supraglottis, glottis, subglottis) with anatomic boundaries. Key structures labeled: epiglottis, pre-epiglottic space, aryepiglottic fold, false vocal fold, ventricle, true vocal fold, paraglottic space, thyroid cartilage, cricoid cartilage, arytenoid cartilage, and anterior commissure. The paraglottic and pre-epiglottic spaces are highlighted as pathways for tumor spread. T-staging criteria are annotated at each level.</image>

<image>Comparison diagram showing voice restoration options after total laryngectomy. Panel A: Tracheoesophageal puncture (TEP) with a one-way valve (Provox) inserted between the trachea and esophagus, showing airflow from the lungs through the valve into the esophagus, vibrating the pharyngoesophageal segment to produce voice. Panel B: Esophageal speech with swallowed air vibrating the PE segment. Panel C: Electrolarynx device held against the neck, transmitting vibrations into the pharynx. Anatomical landmarks including the tracheostoma, neopharynx, and esophagus are labeled.</image>

<image>Flowchart for the management of advanced laryngeal SCC (T3-T4). Decision tree starting with staging workup and assessment of laryngeal function. For T3 with functional larynx: concurrent chemoradiation (organ preservation) as standard, with total laryngectomy reserved for failures (salvage). For T4a with cartilage destruction or non-functional larynx: primary total laryngectomy + adjuvant therapy. Post-chemoradiation assessment with PET/CT at 12 weeks, leading to planned neck dissection only for incomplete nodal response. Salvage laryngectomy pathway with pharyngocutaneous fistula risk highlighted.</image>

Clinical Pearls

Hoarseness is the earliest symptom of glottic carcinoma and enables early diagnosis; supraglottic tumors present late because the primary symptoms are vague (sore throat, otalgia). Concurrent cisplatin + radiation is the standard organ preservation protocol (RTOG 91-11); induction chemotherapy followed by radiation is an alternative for patients who cannot tolerate concurrent cisplatin. Organ preservation does NOT mean organ function preservation: patients may have a preserved larynx that is non-functional (aspiration, aphonia). Overall survival for advanced laryngeal cancer may have declined with widespread organ preservation -- patient selection is crucial; primary surgery may be better for select T4a patients. Vocal fold fixation on examination is T3 disease and is a critical distinction for treatment planning. Post-chemoradiation PET/CT at 12 weeks guides neck management: complete response allows observation; incomplete response requires neck dissection. Salvage laryngectomy after chemoradiation has a 15-30% pharyngocutaneous fistula rate; consider vascularized tissue at the time of surgery. Supracricoid partial laryngectomy is an underutilized option that preserves voice and swallowing for select T2-T3 glottic tumors while achieving oncologic outcomes comparable to total laryngectomy.

References

• Department of Veterans Affairs Laryngeal Cancer Study Group. "Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer." N Engl J Med. 1991;324(24):1685-1690.
• Forastiere AA, Zhang Q, Weber RS, et al. "Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx." J Clin Oncol. 2013;31(7):845-852.
• Steiner W, Ambrosch P. "Endoscopic laser surgery of the upper aerodigestive tract." Thieme. 2000.
• Laccourreye O, Weinstein G, Brasnu D, et al. "Supracricoid partial laryngectomy after failed laryngeal radiation therapy." Laryngoscope. 1996;106(4):495-498.

Read this lecture as Markdown